Melrose Industries plc has delivered 22% annually for investors. Can Volvere plc do the same?

Battle of the turnaround experts: should you buy massive Melrose plc (LON: MRO) or minnow Volvere plc (LON: VLE)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Industrial turnaround specialist Melrose plc (LSE: MRO) has created significant shareholder value since its 2003 listing. Founder and executive chairman Christopher Miller describes the company as a “a sick bay for good industrial companies.”

Take a look at the value created by Miller and co between 2003 and 2015;

  • 22% average annual return on investment since its first deal in 2005.
  • Turned a net shareholder investment of £0.1bn into £2.9bn between October 2003 and 2015.

The Melrose method

Melrose tends to seek out companies that manufacture niche items with repeat demand, such as filters, that will inevitably have to be replaced. These replacement cycles provide the company with some level of revenue visibility. Melrose prefers a strong competitive position within an industry.

Once it has identified and purchased a company, it focuses on improving cash flow through a combination of job cuts, incentive structures, operational tweaks and investment, before hopefully selling for a profit.

For a while Melrose looked cheap, but the successful sale of Elster for £3.3bn to Honeywell woke the market to its potential. Melrose had acquired the company for only £1.8bn back in August 2012.

It doesn’t do things by halves, more often than not buying entire businesses and working on them for a number of years to turn a profit. This approach has yielded fruit so far, but the sheer size of the transactions means Melrose will likely only be as good as its last deal.

With that in mind, lets take a quick look at its most recently acquired improvement project, Nortek. Last year, 73% of its operating profit was sucked out of the company by interest payments. In one fell swoop, Melrose bought it, cleared its debt and has presumably since got to work improving the underlying business.

It’s an interesting situation, so I’d advise you heavily research Melrose’s other business, Brush, before considering an investment. With that in mind, I believe £22m market cap Volvere plc (LSE: VLE) could be a worthwhile alternative pick.

To roll, to turn about

The company’s name is Latin for ‘to roll, turn about, turn round’ and like Melrose, Volvere specialises in buying ailing businesses, improving them and selling at a profit.

Headed by brothers Jonathon and Nicholas Lander, a Cambridge-educated lawyer and a chartered accountant respectively, Volvere shies away from the industrial companies Melrose chases and instead focuses its efforts on ‘people businesses’.

It does this for two reasons;

  1. No one else wants to buy struggling human capital. This creates value opportunities for Volvere.
  2. The brothers have spent their own careers working in people-based businesses and it’s what they’re good at.

It’s an interesting approach, and one that goes against my natural Foolish instincts. After all, an individual can leave, taking key clients or know-how with them. But through an unbroken spell of turnarounds, the company has compounded book value at 14.4% per year since 2002 for a total increase of 513%. And the share price has appreciated at a CAGR of 13% over this period, resulting in a 309% rise.

Right now, the company is working on three turnarounds and the market seems to be placing little faith in its track record as it trades at a slight discount to book value.

So I’d encourage readers to conduct thorough research on Melrose or Volvere before taking the plunge as there are a lot of moving parts to consider.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Zach Coffell has no position in any shares mentioned. The Motley Fool UK owns shares of Melrose. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »